Ganitumab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaPancreatic CancerMetastatic Colorectal CancerEwing SarcomaRhabdomyosarcomaMetastatic Ewing Sarcoma

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

Ganitumab

Amgen

Phase 3

12

Blenoxane

SSequus Pharmaceuticals

Preclinical

253

Oncaspar

SServier

Preclinical

154

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

15

Kenalog

BBausch Health Americas, Inc.

Preclinical

16

Nuvigil

NNuvo Research GmbH

Preclinical

17

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

39

R-CHOP

IIncyte Biosciences Japan GK

Preclinical

110

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

1Show 19 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Ewing sarcoma2 trials

Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

No longer available·JJonsson Comprehensive Cancer Center··NCT03029481

Palbociclib + Ganitumab In Ewing Sarcoma

Terminated·—·Phase 2·NCT04129151·10 enrolled

Locally Advanced Cancer1 trial

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Completed·Radiation Therapy Oncology Group·Phase 1·NCT01298401·8 enrolled

Lymphoma1 trial

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

Completed·Amgen·Phase 1·NCT00562380·64 enrolled

Resistance1 trial

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

Completed·NNantBioScience, Inc.·Phase 2·NCT00891930·74 enrolled

Recurrent Sarcoma1 trial

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Recruiting·MM.D. Anderson Cancer Center·N/A·NCT04199026·20 enrolled

5 more indications

Pancreatic Cancer1 trial

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer

Withdrawn·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT01473303

GAN1 trial

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Completed·Amgen·Phase 2·NCT01327612·12 enrolled

Rhabdomyosarcoma1 trial

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT03041701·14 enrolled

Metastatic Colorectal Cancer1 trial

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Completed·NNantBioScience, Inc.·Phase 1/2·NCT00788957·177 enrolled

Metastatic Ewing Sarcoma1 trial

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02306161·312 enrolled

Details

Drug Info

Related News